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MicroAbstract 
Suboptimal dose intensity of adjuvant chemotherapy is associated with a poor prognosis in patients with 
early stage breast cancer. We investigated the relative dose intensity (RDI) of modern adjuvant 
chemotherapy regimens in patients 65 years and older. An RDI ≥85% was achieved in 177 (63%) of 281 
patients included. Better supportive care of risk groups may further optimise RDI. 
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Abstract 
Introduction 
Maintaining relative dose intensity (RDI) of adjuvant chemotherapy ≥85% is associated with improved 
treatment outcomes in early stage breast cancer (ESBC). Increasing evidence suggests that they can 
maintain optimal RDI of standard chemotherapy regimens. This study investigated the RDI of newer 
adjuvant chemotherapy regimens in this demographic. 
Patients and Methods 
We retrospectively analysed 281 patients ≥65 years who were diagnosed with ESBC and received 
adjuvant chemotherapy across three sites in QLD, Australia during 2010-2015. The primary endpoint 
was the proportion of patients who received an RDI≥85%.  
Results 
The median age at diagnosis was 68 (65-85) years old, with 36.3% over 70 years of age. Patient 
characteristics included tumour stage T3 or T4 (17%) and node positive disease (60%). Common 
chemotherapy regimens included docetaxel/cyclophosphamide (TC) (23%), 5-fluorouracil/epirubicin/ 
cyclophosphamide-docetaxel or paclitaxel (FEC-D/T) (17%), adriamycin/cyclophosphamide-weekly 
paclitaxel (AC-wT) (38%) and docetaxel/carboplatin/Herceptin (TCH) (11%). Primary (15%) and 
secondary (54%) G-CSF was used. RDI≥85% was achieved in 63% of patients. Significant associations 
were noted between reduced RDI and age ≥70 years (p<0.001), Charlson index 1+(p=0.043), initial dose 
reductions (p=0.01), secondary G-CSF use (p=0.45), hospital admission (p<0.001) and febrile neutropenia 
(p=0.007). Treatment-related toxicities were the most common reason for non-completion with high 
rates of hospital admissions (46%) and febrile neutropenia (22%).  
Conclusion 
Our findings suggest that patients ≥ 65 years old with ESBC can maintain an optimal RDI of modern 
chemotherapy regimens. Appropriate geriatric assessment and use of supportive measures such as G-
CSF could better assist select groups to maintain optimal dose intensity. 
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Introduction  
Breast cancer is the leading cause of cancer and the second leading cause of cancer-related deaths 
among Australian women. Its incidence increases with age, with 59% of new diagnoses occurring in 
patients aged 65 years or older and a median age of presentation of 61 years of age.
1
 While the 
prognosis of primary breast cancer has improved significantly in recent decades, this trend is heavily 
skewed towards younger patients. According to the breast cancer mortality database compiled by the 
World Health Organization, women aged between 50 and 69 years and those aged 70 years and above 
have experienced median improvements in mortality during 1989 and 2006 of 21% and 2%, 
respectively.
2
 Recent publications have noted that a potential major reason for this comparatively poor 
prognosis among the elderly cohort is under-utilization of adjuvant chemotherapy in this patient group.
3, 
4
 Older patients have been more likely to receive dose reductions and delays, thus reducing the overall 
relative dose intensity (RDI) of their treatment.
5
  
 
Dose intensity refers to the measure of chemotherapy drug delivered per unit time (mg/m
2
/week) and 
RDI is defined as the received dose intensity relative to the reference dose intensity. RDI is an important 
prognostic factor which reflects the degree of adherence to recommended chemotherapy regimens and, 
by extension, the safety and tolerability of these treatments. Importantly, the maintenance of RDI above 
a minimum optimal threshold of 85% has been shown to correlate with increased rates of disease-free 
survival and overall survival.
6-8
   Literature suggests that a key cause of this age-based discrepancy in 
treatment was the historical consensus that adjuvant chemotherapy treatments are poorly tolerated by 
older patients, compared to their younger counterparts. Several older studies reported significantly 
higher rates of toxicities and mortality associated with first- and second-generation adjuvant regimens 
among elderly breast cancer patients, leading to caution when prescribing chemotherapy in this 
demographic. 
5, 8-10
 However, a growing body of evidence suggests that select older patients tolerate a 
range of adjuvant chemotherapy regimens better than previously thought and that they are capable of 
maintaining optimal dose intensity.
11-14
  
 
The primary aim of this study is to assess whether patients 65 years of age and older who received 
adjuvant chemotherapy for early stage breast cancer maintained an RDI of 85% and over. 
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Materials and Methods 
Subjects and Data Collection 
A retrospective analysis was conducted of all patients aged 65 years or older who underwent surgical 
resection for early stage breast cancer and received adjuvant chemotherapy across three sites in QLD, 
Australia between 2010 and 2015. Patients receiving palliative intent treatment were excluded from the 
study. The primary outcome measure of this study was to assess the proportion of patients reaching a 
relative dose intensity of 85% and over. Secondary outcome measures were to assess factors affecting 
dose intensity including age, body mass index (BMI), Charlson Comorbidity Index, chemotherapy 
protocol and use of Granulocyte Colony Stimulating Factor (G-CSF) as well as toxicity data.  RDI was 
analysed against disease recurrence and patient mortality. Low risk ethical approval 
HREC/15/QRBW/320 was granted for the study by the human research ethics committee with the need 
for individual patient consent waivered. 
Dose Intensity 
RDI was calculated as a ratio of actual dose intensity (ADI) to standard dose intensity (SDI). In order to 
calculate SDI (mg/m2/week), the total chemotherapy dose standard to each protocol was divided by the 
standard duration of that protocol, including all planned cycles. To calculate ADI, the total 
chemotherapy dose received by each patient during their treatment was divided by the duration for 
which each patient received that chemotherapy protocol. If a patient received less than the planned 
number of cycles, then a dose of 0 was assigned to each missed cycle. The duration of treatment was 
calculated as the sum of the time taken for each cycle received and the standard time required for any 
missed cycles. Trastuzumab was not included in calculations and dose intensity was only recorded for 
the first chemotherapy regimen prescribed, until its completion or discontinuation.  
Statistical Analysis 
Patient characteristics, clinical and pathological factors were summarised using frequencies and percent 
for categorical variables and median (interquartile range (IQR)) for continuous variables. BMI categories 
were collapsed into <25 / and ≥ 25	/ for logistic regression analyses.  Associations between 
RDI and factors of interest were examined using a chi-square test or Fisher’s exact test where 
appropriate. Association between RDI and age group was further examined using univariable and 
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multivariable logistic regression analyses. SPSS was used to analyse the data. The level of statistical 
significance was set at 0.05. 
Results  
Patient Characteristics 
A retrospective review yielded 281 eligible patients whose clinical and pathological characteristics are 
listed in Table 1. The median age at diagnosis was 68 (65-85) years old with 102 patients (36%) aged 70 
and above. Most patients presented with hormone receptor positive (77%), HER2 negative (77%), early 
T stage 1/2 (83%), node positive (60%), invasive ductal carcinoma (75%) and underwent mastectomy 
(64%) followed by post-operative radiotherapy (67%). Commonly used adjuvant chemotherapy 
regimens included adriamycin/cyclophosphamide-weekly paclitaxel (AC-wT), docetaxel/ 
cyclophosphamide (TC), 5-fluorouracil/ epirubicin/ cyclophosphamide-docetaxel (FEC-D), 5-fluorouracil/ 
epirubicin/ cyclophosphamide-paclitaxel (FEC-T), FEC 100, docetaxel/ doxorubicin/ cyclophosphamide 
(TAC), docetaxel/ carboplatin/ Herceptin (TCH), and weekly paclitaxel.  
Compared to their older counterparts, patients aged 65-69 years had significantly higher rates of T1/2 
disease (67%, compared to 33% of older patients aged ≥70 years), higher rates of HER 2 negativity (68%, 
compared to 32% of older patients) and higher rates of wide local excision (78%, compared to 22% of 
older patients). Older patients received equivalent rates of AC-wT (48% aged ≥70 years, compared to 
52% of patients aged 65 to 69 years) but significantly higher rates of weekly paclitaxel (75%, compared 
to 25% of younger patients) and significantly lower rates of TC (20%, compared to 80% of younger 
patients), TAC (12%, compared to 88% of younger patients) and FEC-D/T (29%, compared to 71% of 
younger patients). There was no significant difference between other parameters including Charlson 
comorbidity index, ECOG performance status, TNM stage, hormone receptor status, number of 
admissions, rates of febrile neutropenia or use of G-CSF.  
Tolerability and Feasibility of Chemotherapy 
A total of 177 (63%) patients achieved an RDI ≥85%, with 121 (43%) maintaining an RDI of 100%. An RDI 
of <65 occurred in 49 (17%) of patients. Initial dose reduction or capping of the dose occurred in 29 
(10%) of patients. Dose reductions occurred in 64 patients (23%), dose delays in 58 (21%) and dose 
delays over 2 weeks in 17 (6%) of patients. A total of 178 (63%) of patients completed all prescribed 
chemotherapy cycles, with the most common reasons for non-completion being treatment-related 
toxicities including febrile neutropenia in 62 (22%) and peripheral neuropathy in 145 (52%). Primary G-
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CSF was used in 41 (15%) patients with the requirement of secondary G-CSF in 148 (54%) of patients. A 
high rate of primary G-CSF prophylaxis was used in TAC (75%) and FEC-D (58%) chemotherapy regimens. 
Febrile neutropenia occurred most often in TC (34%) followed by TCH (30%) chemotherapy protocols in 
those patients where primary prophylaxis was not given (table 2). A total of 129 (46%) of patients 
experienced one or more admissions with 49 (17%) experiencing two or more admissions. Treatment 
related toxicities and the use of G-CSF was not significantly different amongst patients aged 65-69 
compared to those aged 70 and over.  
Factors Associated with Relative Dose Intensity 
There was a significant association between reduced RDI and age group >70 (p<0.001), Charlson index of 
1+ (p=0.043), initial dose reduction (p=0.001), admission to hospital (p<0.001), rate of febrile 
neutropenia (p=0.007) and requirement for secondary G-CSF use (p=0.045). No significant association 
was noted between RDI and primary G-CSF use, BMI or individual chemotherapy protocol (table 3).   
The results of univariable and multivariable logistic regression analyses of the relationship between RDI 
and age group and Charlson index are shown in table 4. Univariable analyses demonstrate that Charlson 
index and age were significantly associated with RDI (p = 0.044 and p<0.001, respectively). The odds of 
achieving optimum dose intensity was 75% lower (OR: 0.25, 95% CI: 0.15-0.41) in patients aged ≥70 
years compared to the younger age group and 33% lower (OR: 0.67, 95%CI: 0.46-0.97) in patients with 
higher Charlson index (> 1) compared to those with a Charlson index of 0. The effect of age group was 
further examined by adjusting for Charlson index respectively in multivariable analyses. The effect of age 
group remained statistically significant with no considerable changes in odds ratios.  
Clinical Outcomes 
The median length of follow up was 43 (6-117) months. There was no statistically significant association 
between RDI and recurrence or overall mortality with 37 events of breast cancer recurrence and 32 
deaths (see table 5).  
Discussion 
Maintenance of RDI 
The results of this study demonstrate that a significant proportion of selected older patients with early 
stage breast cancer are capable of maintaining an optimal dose intensity of adjuvant chemotherapy. An 
RDI of 85% or greater was achieved by 63% of the cohort, with 43% of patients maintaining an RDI of 
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100%. We have compared these findings to those of several recent studies (table 6). In their 
retrospective review, Raza et al. (2009) found that a comparable 65% of patients aged 65 years and over 
maintained an RDI of ≥85% while receiving adjuvant chemotherapy.
12
 However, studies by 
Nghamphaiboon et al. (2011), Oladipo et al. (2012) and Lyman et al. (2013) showed higher rates of 
optimal RDI among elderly patients: 75%, 78% and 81%, respectively.
11, 13, 15
  There are several key 
methodological discrepancies that may account for these differences in outcomes. A large proportion of 
our cohort was treated with third-generation anthracycline- and taxane-based chemotherapy regimens 
such as FEC-D, FEC-T and TAC, whereas the other studies relied largely on first- and second-generation 
treatments. The only other use of newer protocols was by Raza et al. (2009) and Oladipo et al. (2012) in 
which 22% and 2% of patients, respectively, received FEC-D.12, 13  
Another key difference is that several of these studies used considerably higher rates of primary 
prophylactic G-CSF in order to minimize rates of treatment-related febrile neutropenia and thus improve 
dose intensity. Although the present study failed to find an association between primary G-CSF use and 
RDI, it is important to note that the rate of primary G-CSF use among our cohort was too low to make 
firm conclusions. However, the use of secondary G-CSF did statistically improve the dose intensity. In the 
patient cohorts investigated by Nghamphaiboon et al. (2012) and Lyman et al. (2013), 100% and 81 % of 
patients received primary G-CSF prophylaxis, respectively, whereas only 15% of our patients received 
this treatment.
11, 15
 This approach is widely supported in recent literature and current European and 
American consensus panels recommend consideration of G-CSF use in patients undergoing 
intermediate- or high-risk regimens who are at additional risk of developing febrile neutropenia, 
including those aged 65 years or above. 3, 4, 16, 17 However, under the Australian Pharmaceutical Benefits 
Scheme, G-CSF use in the adjuvant chemotherapy setting is limited. Growth factor support is only 
licenced for primary prophylaxis in initial cycles of certain regimens (such as TAC, which is infrequently 
used in the elderly population at present) and in other regimens only as secondary prophylaxis of febrile 
neutropenia or prolonged severe neutropenia.
18
 This relative lack of local supportive care limits the 
applicability of international clinical trial data in Australia. Finally, as neither Raza et al. (2009) nor 
Nghamphaiboon et al. (2012) were primarily investigating elderly patients, who only comprised 22% 
(n=37) and 14% (n=24) of participants, respectively, the statistical power of their conclusions regarding 
patients aged 65 and over is limited compared to this large retrospective cohort.
12, 15
  
Factors affecting RDI  
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Our results implicate age as an independent risk factor for reduced dose intensity; patients aged 70 
years and over were significantly less likely to maintain an optimal dose intensity than those who were 
65 to 69 years old. When attempting to correlate our findings with other literature, it was noted that 
there is a lack of research involving elderly cancer patients, especially those over 70 years of age (with 
some studies actively excluding this age bracket) and that the studies that do exist have yielded mixed 
results.
13, 19
 Lyman et al. (2013) found that increasing age was not associated with risk for a sub-optimal 
RDI and although Oladipo et al. (2012) noted that fewer patients aged 70 years maintained an RDI ≥85% 
this figure fell short of statistical significance.11, 13 By contrast, Shayne et al. (2007) investigated dose 
intensity in cancer patients aged 70 years and above and found that increasing age was associated with 
lower RDI (p = 0.03), most markedly in the age bracket of 80 years and above. As their cohort comprised 
976 patients, the statistical power of these results is greater than that of the previously mentioned 
studies, however their results are not directly comparable to ours as only 13% of the patients had breast 
cancer and only 52% were treated with curative intent.
20
 Other studies have implicated age ≥70 as a 
significant predictor of reduced RDI of chemotherapy, but none with a specific focus on early stage 
breast cancer.
21, 22
 In our study, there was significant variation in the chemotherapy protocols prescribed 
to these two age groups. Older patients received lower rates of TC, FEC-D and TAC chemotherapy 
regimens and higher rates of weekly paclitaxel alone deemed more tolerable. Older patients with Her2 
positive breast cancer might have continued on an anti-Her2 agent upon ceasing chemotherapy as an 
alternative, more tolerable treatment option.  
Interestingly, Charlson Comorbidity Index scores were comparable between both age groups, which 
contradicts the higher rates of comorbidity reported among elderly patients in the literature.23 This 
might simply reflect a selection bias of patients being seen in the medical oncology department for 
consideration of adjuvant therapies where patients with comorbidities are less likely to be referred and 
ultimately treated.  Charlson Index was shown to have a significant impact on RDI maintenance, albeit to 
a lesser degree than age, which is in keeping with past research into this patient demographic.
24
 One 
potential cause for this trend is the fact that co-existing major illness is known to adversely affect 
adherence to institutional therapeutic guidelines.
4, 25
 However, as stated previously, the differences that 
we found in chemotherapy regimen prescription between age groups was not accounted for by co-
morbidity status.  
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Obesity is another patient-related factor that has been independently implicated in causing reductions 
of RDI; however, this finding was not replicated among our cohort.
26, 27
  While a higher proportion of 
patients with a BMI >24.9 failed to reach optimal DI, this assocation remained statistically insignificant.  
Although there was a significant difference in choice of chemotherapy and maintaining RDI, there is 
likely to be a selection bias particularly related to comorbidities and performance status. For example, 
clinicians are more inclined to choose chemotherapy for Her2 positive early breast cancer, so that the 
patients can receive concurrent trastuzumab. Therefore, patients may be included for chemotherapy 
who otherwise would have received endocrine treatment without chemotherapy. This may explain the 
reduced RDI <85% with TCH (53%) and weekly paclitaxel (67%). In general terms, it has been shown that 
relative to first-generation adjuvant therapies, second-generation regimens are more efficacious in the 
treatment of early breast cancer and, importantly, are well tolerated in older patients.
28
 While there is a 
comparative lack research into the tolerability of third-generation adjuvant cytotoxic regimens in this 
demographic, there is some evidence to suggests that newer, dose-intense anthracycline-based 
regimens are equally as effective across age groups, that they are significantly more effective than first 
generation regimens, and that they are tolerated in healthy elderly patients in the setting of primary G-
CSF prophylaxis.
5, 10
 Raza et al. (2009) recorded higher rates of optimal RDI with AC-wT, FEC-D and FEC-
100 (96%, 95% and 71%, respectively), however, statistical power was also a limiting factor in this 
study.
12
 
As expected, hospital admission during treatment was associated with significant reductions in RDI. It is 
important to note that the majority of reductions in RDI occurred after the first cycle and are thus 
attributable to unplanned factors such as treatment-related toxicity. The most pronounced treatment-
related toxicity experienced by our cohort was febrile neutropenia (22%). RDI significantly improved 
with secondary GCSF use. The use of primary GCSF prophylaxis could ameliorate the risk of febrile 
neutropenia in this population and further improve RDI.   
Prognostic Significance of RDI 
There were few recurrences or deaths to date amongst our cohort within the short follow up period. As 
such, we did not find a significant association between RDI and cancer recurrence, all-cause mortality or 
cancer-specific mortality.  Although some studies fail to report worse outcomes associated with 
reductions in RDI, the weight of research supports the prognostic significance of dose intensity.
6, 7, 29, 30
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Early breast cancer survival rates associated with DI < 65% are comparable to those of untreated control 
groups and a dose reduction of 20% has been show to halve rates of cure in this demographic.
31
  
Study Limitations  
This study has a number of limitations, chief among them being the relatively small sample size of this 
which resulted in insufficient statistical power to analyse the effect of chemotherapy regimen on RDI. In 
addition, the brief follow-up period did not allow for conclusive assessment of the prognostic 
significance of RDI.  Other sources of inaccuracy are the broad manner in which toxicity data is recorded 
as per the CTCAE 1.1 reference and the difficulty in accessing records of non-Queensland Health hospital 
admissions. Finally, selection bias must also be taken into account: poor health and performance status 
likely prevented many older; less fit patients from being referred for consideration of adjuvant 
chemotherapy and, in the event of successful referral, these patients may have been less likely to 
receive treatment than their younger counterparts. As such feasibility and tolerability and data is likely 
skewed by the resulting younger, healthier cohort. However, this is conjecture as total numbers of 
patients considered for referral and for treatment were not recorded. 
Conclusion 
Our results show that patients ≥65 years with early stage breast cancer can maintain an optimal RDI 
through a range of newer adjuvant chemotherapy protocols; however, tolerance of these regimens 
remains suboptimal, with high rates of treatment-related toxicities necessitating admission and 
treatment delay. Given its prognostic importance, it is essential to minimize reductions in RDI through 
the early and widespread use of supportive measures including secondary G-CSF prophylaxis, 
particularly in at risk populations identified in this study, as well as through the effective management of 
treatment-related toxicities. The routine use of comprehensive geriatric assessment in older patients 
may have a role to play in the latter, although more research is required in this area.
32
 There continues 
to be a paucity of clinical research in elderly cancer patients necessitating larger scale investigation into 
factors influencing RDI in this demographic, especially with regards to newer chemotherapy regimens.  
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Table 1.  Patient Demographics and Treatments Used 
Variables N (%) Variables N (%) 
Gender  Hormone Receptor Status  
   Female 279 (99)    Positive 217 (77) 
   Male 2 (1)    Negative 64 (23) 
BMI category  HER2 status  
   <25 	/
 84 (30)    Positive 65 (23) 
   ≥ 25		/
 197 (70)    Negative 216 (77) 
Charlson index  Surgery   
    < 1 178 (63)    Wide Local Excision 102 (36) 
   1 or above 103 (37)    Mastectomy 179 (64) 
ECOG performance status  Adjuvant External Radiation 
therapy 
 
    < 1 243 (87)    Yes 188 (67) 
   1 or above 38 (13)    No 93 (33) 
Tumour stage   Neoadjuvant therapy  
   1/2 234 (83)    Yes 21 (8) 
   3/4 47 (17)    No 260 (92) 
Simplified tumour type  Chemotherapy Protocols Used  
   IDC 210 (75)    AC-wT 106 (38) 
   ILC 44 (16)    TC 64 (23) 
   Other 27 (9)    FEC-D/ FEC-T 48 (17) 
     TAC 8 (3) 
Positive lymph nodes     TCH 30 (11) 
    < 1 111 (40)    Paclitaxel 12 (4) 
   1 or above 170 (60)    FEC 100 8 (3) 
     Other 5 (1) 
    
Body Mass Index (BMI), Eastern Cooperative Oncology Group (ECOG), invasive ductal carcinoma (IDC), 
invasive lobular carcinoma (ILC), human epidermal growth factor receptor 2 (HER 2), 
adriamycin/cyclophosphamide-weekly paclitaxel (AC-wT), docetaxel/ cyclophosphamide (TC), 5-
fluorouracil/ epirubicin/ cyclophosphamide-docetaxel (FEC-D), 5-fluorouracil/ epirubicin/ 
cyclophosphamide-paclitaxel (FEC-T), docetaxel/ doxorubicin/ cyclophosphamide (TAC), docetaxel/ 
carboplatin/ Herceptin (TCH). 
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Table 2. Association of G-CSF Use and Rate of Febrile Neutropenia with Chemotherapy Protocol Used. 
 
 
Granulocyte Colony Stimulating Factory (G-CSF), Febrile Neutropenia (FN), 
adriamycin/cyclophosphamide-weekly paclitaxel (AC-wT), docetaxel/ cyclophosphamide (TC), 5-
fluorouracil/ epirubicin/ cyclophosphamide-docetaxel (FEC-D), docetaxel/ doxorubicin/ 
cyclophosphamide (TAC), docetaxel/ carboplatin/ Herceptin (TCH). 
  
 Chemotherapy protocol 
AC-wT TC Paclitaxel TCH FEC-D TAC 
N (%) N (%) N (%) N (%) N (%) N (%) 
Primary 
G-CSF 
Y  
 
 2 2% 5 8% 0 0% 0 0% 28 58% 6 75% 
N 
 
 
 
 104 98% 59 92% 12 100% 30 100% 20 42% 2 25% 
FN 
Y 
 
15 14% 20 34% 0 0% 10 33% 6 30% 1 50% 
N 
 
89 86% 39 66% 12 100% 20 67% 14 70% 1 50% 
Secondary 
G-CSF 
Y  
 
 73 71% 38 61% 0 0% 18 60% 8 17% 2 25% 
N 
 
  30 29% 24 39% 11 100% 12 40% 40 83% 6 75% 
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Table 3. Associations Between Relative Dose Intensity (RDI) and Clinical-Pathological Factors 
Body Mass Index (BMI), Granulocyte Colony Stimulating Factory (G-CSF), adriamycin/cyclophosphamide-
weekly paclitaxel (AC-wT), docetaxel/ cyclophosphamide (TC), 5-fluorouracil/ epirubicin/ 
cyclophosphamide-docetaxel (FEC-D), 5-fluorouracil/ epirubicin/ cyclophosphamide-paclitaxel (FEC-T), 
docetaxel/ doxorubicin/ cyclophosphamide (TAC), docetaxel/ carboplatin/ Herceptin (TCH). 
 
Variable RDI <85%: N (%)    RDI ≥85 %: N (%) p-value 
 
Age group   <0.001 
   65 to 69 45 (25) 134 (75)  
   70 and above 59 (58) 43 (42)  
BMI     0.27 
   18.5 to 24.9 27 (32) 57 (68)  
   25 and above 77 (39) 120 (61)  
Charlson Index     0.043 
    < 1 58 (33) 120 (67)  
   1 or above 46 (45) 57 (55)  
Initial dosage   0.001 
   <100% 19 (65) 10 (35)  
   100% 85 (34) 167 (66)  
Admissions   <0.001 
   Yes 68 (54) 58 (46)  
   No 36 (23) 119 (77)  
Febrile neutropenia    0.007 
   Yes 32 (52) 30 (48)  
   No 72 (33) 147 (67)  
Primary G-CSF    0.447 
   Yes 13 (32) 28 (68)  
   No 91 (38) 149 (62)  
Secondary G-CSF    0.045 
   Yes 45 (30) 103 (70)  
   No 53 (42) 73 (58)  
Peripheral Neuropathy   0.564 
   Yes 56 (39) 89 (61)  
   No 48 (35) 88 (65)  
Chemotherapy Protocol   0.029 
   AC-T 40 (38) 66 (62)  
   TC 16 (25) 48 (75)  
   FEC-D/FEC-T 18 (37) 30 (63)  
   TAC 1 (13) 7 (88)  
   TCH 16 (53) 14 (47)  
   Paclitaxel 8 (67) 4 (33)  
   Other (FEC-100, AC) 5 (38) 8 (62)  
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Table 4. Logistic Regression Analyses of Factors Affecting Relative Dose Intensity (RDI) 
 Univariable Multivariable 
   Age and Charlson index 
Variable Crude OR  
(95% CI) 
p-value Adjusted OR 
(95% CI) 
p-value 
Age group  <0.001  < 0.001 
   65 to 69 1.00  1.00  
   70 and above 0.25 (0.15-0.41)  0.24 (0.14-0.41)  
Charlson index   0.034  0.038 
    < 1 1.00  1.00  
   1 or above 0.67 (0.46-0.97)  0.57 (0.34-0.97)  
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Table 5. Associations Between Relative Dose Intensity (RDI) and Outcomes of Chemotherapy  
Variable RDI <85%: n (%) RDI ≥ 85%: n (%) p-value 
Recurrence    0.399 
   Yes 16 (15) 21 (12)  
   No 88 (85) 156 (88)  
All-Cause Mortality    0.951 
   Yes 12 (12) 20 (11)  
   No 92 (88) 157 (89)  
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Table 6. Retrospective Studies of Relative Dose Intensity (RDI) of Adjuvant Chemotherapy in Older 
Patients with Breast Cancer 
 Med Onc 2009 
(13) N = 37 
Med Onc 2012 
(15) N=24 
Breast J 2012 
(14) N= 101  
Br Ca R+T 2013 
(12) N = 117 
Current study 
N = 281 
Median Age n/a 72 69 n/a 68 
Chemo Protocol      
   CMF - - 8 - - 
   FEC-100 22 - 77 - 8 
   AC - - 14 9 - 
   AC-T 7 - - 18 106 
   TC - 24 - 61 64 
   TCH - - - 15 30 
   FEC-D/T 8 - 2 - 48 
   TAC - - - - 8 
   Paclitaxel - - - - 12 
RDI ≥85% 65% 75% 78% 81% 63% 
Dose delay > 7 days 10.8% 8% 44% 24% 21% 
Primary G-CSF prophylaxis 0 100% n/a 81% 15%  
Granulocyte Colony Stimulating Factory (G-CSF), adriamycin/cyclophosphamide-weekly paclitaxel (AC-
wT), docetaxel/ cyclophosphamide (TC), 5-fluorouracil/ epirubicin/ cyclophosphamide-docetaxel (FEC-D), 
5-fluorouracil/ epirubicin/ cyclophosphamide-paclitaxel (FEC-T), docetaxel/ doxorubicin/ 
cyclophosphamide (TAC), docetaxel/ carboplatin/ Herceptin (TCH). 
 
 
